Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pumitamig plus chemotherapy versus bevacizumab plus chemotherapy in previously untreated unresectable or metastatic colorectal cancer
NL-OMON59485Phase 3Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of pumitamig in colorectal cancer (CRC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Objective response rate, Progression-free survival and 1 more. Planned start Feb 2026; status: withdrawn.
02
Drugs
pumitamig
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON59485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59485.